The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions

The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyer, Sunil Girish, Elias, Laila, Stanchina, Michele, Watts, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889825/
https://www.ncbi.nlm.nih.gov/pubmed/36741714
http://dx.doi.org/10.3389/fonc.2022.1062524
_version_ 1784880814881767424
author Iyer, Sunil Girish
Elias, Laila
Stanchina, Michele
Watts, Justin
author_facet Iyer, Sunil Girish
Elias, Laila
Stanchina, Michele
Watts, Justin
author_sort Iyer, Sunil Girish
collection PubMed
description The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective therapies targeting the mutant protein that drives the disease, leading to the chemotherapy-free approach to cure almost all patients. In this review, we discuss the paradigm of treatment of APL in 2023, reinforce the high risk of early death without prompt initiation of treatment at first clinical suspicion, and dedicate a special focus to novel agents and future directions to improve cure rates and quality of life in patients affected by APL.
format Online
Article
Text
id pubmed-9889825
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98898252023-02-02 The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions Iyer, Sunil Girish Elias, Laila Stanchina, Michele Watts, Justin Front Oncol Oncology The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective therapies targeting the mutant protein that drives the disease, leading to the chemotherapy-free approach to cure almost all patients. In this review, we discuss the paradigm of treatment of APL in 2023, reinforce the high risk of early death without prompt initiation of treatment at first clinical suspicion, and dedicate a special focus to novel agents and future directions to improve cure rates and quality of life in patients affected by APL. Frontiers Media S.A. 2023-01-18 /pmc/articles/PMC9889825/ /pubmed/36741714 http://dx.doi.org/10.3389/fonc.2022.1062524 Text en Copyright © 2023 Iyer, Elias, Stanchina and Watts https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Iyer, Sunil Girish
Elias, Laila
Stanchina, Michele
Watts, Justin
The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions
title The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions
title_full The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions
title_fullStr The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions
title_full_unstemmed The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions
title_short The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions
title_sort treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889825/
https://www.ncbi.nlm.nih.gov/pubmed/36741714
http://dx.doi.org/10.3389/fonc.2022.1062524
work_keys_str_mv AT iyersunilgirish thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections
AT eliaslaila thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections
AT stanchinamichele thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections
AT wattsjustin thetreatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections
AT iyersunilgirish treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections
AT eliaslaila treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections
AT stanchinamichele treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections
AT wattsjustin treatmentofacutepromyelocyticleukemiain2023paradigmadvancesandfuturedirections

Ejemplares similares